Expression of IL-35 in patients with acute-on-chronic liver failure and its clinical significances

Objective To investigate the dynamic expression of serum IL-35 in patients with acute-on-chronic liver failure(ACLF) and its clinical significance. Methods Serum levels of IL-35 were detected by ELISA in 28patients with HBV-SACLF, 28 patients with chronic hepatitis B and 28 healthy adults. The dynamic changes of IL-35 were observed during the early, middle, and advanced stage of SACLF. The differences in IL-35 expression were compared between the survival group and nonsurvival group. The relationship between IL-35 and HBV-DNA, ALT,and AST was determined by multiple linear regression. Results The concentration of IL-35 was(178.26 ± 52.32)pg / mL in the healthy group,(426.83 ± 236.29) pg / mL in CHB group, and(1 087.00 ± 436.26)pg / mL in SACLF group, it was higher in SACLF patients than in CHB patients and healthy adults(F = 9.95, P 0.01); there were significant differences among the three groups. The concentration of IL-35 was(1 539.00 ± 285.72)pg / mL in the early stage,(1 082.94 ± 333.90)pg / mL in the middle stage, and(636.80 ± 169.00)pg / mL in the advanced stage,with significant differences(F = 3.81, P = 0.02); and it did not differ significantly between the survival group and the nonsurvival group(t′ = 0.46, P = 0.65). IL-35 was associated with HBV-DNA and ALT in the early stage of SACLF(P = 0.01 and P = 0.02). Conclusions Serum IL-35 concentration obviously elevates in SACLF patients.It increases in the early stage and declines in the middle and advanced stages. IL-35 is positively related with HBVDNA and ALT can partly reflect the immune level and prognosis in patients.